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Abstract: Neuroblastoma is a malignancy arising from the developing sympathetic nervous system 
and the most common and deadly cancer of infancy. New therapies are needed to improve the 
prognosis for high-risk patients and to reduce toxicity and late effects. Spleen tyrosine kinase (SYK) 
has previously been identified as a promising drug target in various inflammatory diseases and 
cancers but has so far not been extensively studied as a potential therapeutic target in 
neuroblastoma. In this study, we observed elevated SYK gene expression in neuroblastoma 
compared to neural crest and benign neurofibroma. While SYK protein was detected in the majority 
of examined neuroblastoma tissues it was less frequently observed in neuroblastoma cell lines. 
Depletion of SYK by siRNA and the use of small molecule SYK inhibitors significantly reduced the 
cell viability of neuroblastoma cell lines expressing SYK protein. Moreover, SYK inhibition 
decreased ERK1/2 and Akt phosphorylation. The SYK inhibitor BAY 61-3606 enhanced the effect of 
different chemotherapeutic drugs. Transient expression of a constitutive active SYK variant 
increased the viability of neuroblastoma cells independent of endogenous SYK levels. Collectively, 
our findings suggest that targeting SYK in combination with conventional chemotherapy should be 
further evaluated as a treatment option in neuroblastoma. 
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1. Introduction 
Tyrosine kinases are important mediators of cellular functions such as proliferation, 
differentiation, metabolism, and survival. As tyrosine kinases are frequently deregulated in e.g. 
inflammatory diseases and cancer they are among the most attractive drug targets [1–3]. Spleen 
tyrosine kinase (SYK) is a 72 kDa non-receptor tyrosine kinase consisting of two SRC homology 2 
(SH2) domains and a kinase domain joined by two linker regions, interdomains A and B [4]. A shorter 
SYK splice variant lacking 23 amino acids in the linker region B (SYK(S) or SYK B) has also been 
described in various cell types [5–7]. 
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SYK is a multifunctional protein. It mediates inflammatory responses by linking immune cell 
receptors to various intracellular signaling networks and exhibits, for example, a pivotal role in B-cell 
development [4,8,9]. Among its various functions, SYK promotes, in concert with PKCδ, the 
expression of anti-apoptotic Mcl-1 in B-cell chronic lymphocytic leukemia (CLL) [10] and regulates 
actin filament assembly and dynamics through phosphorylation of cortactin and cofilin in ovarian 
cancer, thereby promoting migration and invasion [11]. Furthermore, phosphorylated SYK has been 
observed in specific cell types and areas of the developing nervous system and diverse functions have 
been described [12–14]. 
Widely expressed in hematopoietic cells [15,16], SYK is a promising therapeutic target in 
inflammatory diseases (including rheumatoid arthritis, allergies, systemic lupus erythematosus, and 
chronic immune thrombocytopenia) [17–19] as well as in different hematological malignancies such 
as CLL [10,20,21], non-Hodgkin lymphoma [22], and acute myeloid leukemia (AML) [23].  
However, SYK expression is not restricted to hematopoietic cells and its presence has been 
described, among others, in epithelial, endothelial, and neuronal cells as well as in different solid 
tumors [24,25]. The role of SYK in the tumorigenesis of both hematological and solid malignancies is 
highly complex, tumor-specific and cell type-dependent, as both tumor promoting and suppressing 
functions have been described [25].  
A tumor-suppressing role for SYK has been demonstrated in e.g. breast cancer [26], pancreatic 
cancer [27], melanoma [28], hepatocellular carcinoma [29] as well as childhood pro-B-ALL [30]. In 
contrast, SYK has been shown to be pro-tumorigenic in prostate cancer [31], small-cell lung cancer 
[32], ovarian cancer [11,33], glioma [34], pediatric retinoblastoma [35], and Ewing sarcoma [36]. 
Of note, distinct functions of the two SYK splice variants have also been demonstrated. While 
the longer SYK variant suppressed breast cancer invasiveness, the shorter variant SYK B did not [37]. 
Neuroblastoma is a malignancy of early childhood with 90% of patients diagnosed below the 
age of 10 [38]. Worldwide, neuroblastoma accounts for 12.5% of cancer cases in children of age 0 to 4 
years [39]. Arising from the developing sympathetic nervous system, the majority of primary tumors 
occur in the adrenal gland [38]. About 50% of neuroblastomas are classified as low- and very-low-
risk with a very good prognosis and receive minimum therapy [38]. In contrast, the treatment of high-
risk neuroblastomas remains a challenge. Despite intensive therapy, about 50% of patients are 
refractory to first-line treatment or relapse within two years [40]. 
With the increasing understanding of neuroblastoma biology and the identification of druggable 
protein kinase targets such as ALK and Aurora A kinase as well as the MAPK and PI3K/mTOR/Akt 
signaling pathways targeted therapies, both alone and in combination with conventional drugs, 
provide new promising treatment options [41]. The aim of the present study was to investigate the 
expression of SYK in neuroblastoma tumor tissues as well as neuroblastoma cell lines and to evaluate 
its use as a potential therapeutic target.  
2. Results 
2.1. SYK Is Expressed in Neuroblastoma Tissue 
We examined SYK gene expression using the publicly available R2: Genomics analysis and 
visualization platform (http://r2.amc.nl) and observed that SYK expression was higher in four 
different neuroblastoma cohorts compared to neural crest cells and benign neurofibroma (Figure 1A). 
Furthermore, we evaluated the presence of SYK protein in neuroblastoma and ganglioneuroma 
using immunohistochemistry (IHC). Supplementary Table S1 displays the clinical features of the 
neuroblastoma tumors used in this study. SYK was present at varying levels in 40 out of 42 
neuroblastomas and 3 out of 3 ganglioneuromas (Table 1). Figure 1B,C display a representative 
staining of SYK in non-MYCN-amplified and MYCN-amplified tumors, respectively. In both, the 
cytoplasm and the nucleus, a positive SYK staining was observed. SYK-positive tumor cells were 
present in 31 out of 32 non-MYCN-amplified neuroblastomas and in 9 out of 10 MYCN-amplified 
tumors (Table 1). 
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Figure 1. SYK is expressed in neuroblastoma tissue. Gene expression data were analyzed using the 
R2 database http://r2.amc.nl. (A) The expression of SYK was compared between neural crest 
(Etchevers n = 5), benign neurofibroma (Miller n = 86) and 4 neuroblastoma cohorts (cohort 1: Versteeg 
n = 88, cohort 2: Delattre n = 64, cohort 3: Hiyama n = 51, cohort 4: Lastowska n = 30). The presence of 
SYK protein (B and C) and phosphorylation at Tyr525 (D and E) were determined in neuroblastoma 
primary tissue using immunoperoxidase staining. (B) and (D) display a staining of a non-MYCN-
amplified tumor and (C) and (E) show a MYCN-amplified tumor. Images were captured at a 
magnification of 900×. The displayed images are representative stainings from a panel of 
neuroblastoma tumors. 






Neuroblastoma 40 (42) 38 (40) 
Non-MYCN-amplified 31 (32) 29 (31) 
MYCN amplified 9 (10) 9 (9) 
* Treated tissue 11 (13) 10 (11) 
* Untreated tissue 26 (26) 25 (26) 
Ganglioneuroma 3 (3) 3 (3) 
* For three tumor tissue samples the information concerning prior treatment was unavailable. 
Using Fisher’s exact test we determined that there was no significant difference in the presence 
of SYK protein between MYCN-amplified and non-amplified tumors (p = 0.4239). However, 
examining different neuroblastoma datasets in the R2: Genomics analysis and visualization platform, 
we observed a significant negative correlation between MYCN and SYK expression (Supplementary 
Figure S1A displaying a representative dataset). In contrast, we found a significant positive 
correlation between SYK and MYC expression (Supplementary Figure S1B). Furthermore, we 
evaluated whether there was a difference in the presence of SYK in tumors that were treated with 
chemotherapy prior to surgery compared to untreated tumors. All 26 untreated tumor samples and 
11 out of 13 treated tumor samples were SYK-positive. This difference was however not significant 
(Fisher’s exact test p = 0.1053). Of note, surgery was performed after at least 10–14 days of washout. 
Hence, no acute chemotherapy-induced regulation of genes should be expected. 
Additionally, the presence of SYK phosphorylated at Tyr525, located within the activation loop 
of the kinase domain, was examined as an indication for active SYK [8,42]. Figure 1D,E display a 
representative staining of p-SYK in non-MYCN-amplified and MYCN-amplified tumors. A strong 
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nuclear staining, as well as some cytoplasmic staining, was observed. Phospho-SYK was present in 
29 out of 31 non-MYCN-amplified tumors, 9 out of 9 MYCN-amplified tumors, 25 out of 26 untreated 
tumors, and 10 out of 11 treated tumors (Table 1).  
Examples for SYK- and p-SYK-negative tumors are displayed in Supplementary Figure S2A and 
S2B. To ensure the specificity of the labeling, a corresponding isotype control antibody was used 
instead of the primary antibodies with which no apparent staining was observed (Supplementary 
Figure S2C). 
2.2. SYK mRNA and to a Lesser Extend SYK Protein Are Present in Neuroblastoma Cell Lines 
Using RT-PCR, western blot and immunocytochemistry (ICC) we examined the presence of SYK 
mRNA and protein in neuroblastoma cell lines. The majority of the neuroblastoma cell lines express 
SYK mRNA at varying levels (Figure 2A). However, SYK protein was detected by western blotting 
in only two of 10 neuroblastoma cell lines, even after long exposure times (Figure 2B). Interestingly, 
we noticed that the cell lines with absent or very low SYK mRNA levels are MYCN-amplified cell 
lines (SK-N-BE(2), SK-N-DZ, Kelly and IMR-32). 
 
Figure 2. Cont. 
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Figure 2. SYK mRNA and to a lesser extend SYK protein are expressed in neuroblastoma cell lines. 
(A) RT-PCR analysis demonstrating the expression of both SYK mRNA variants in different 
neuroblastoma cell lines. U937 cells were used as a positive control (PC). NTC, no template control. 
(B) Expression of SYK protein was determined by western blot. THP-1 cells were used as a positive 
control. Immunofluorescence labeling of SYK (green) in SH-SY5Y (C), LAN-6 (D) and SK-N-BE(2) 
cells (E). The nuclei (blue) were stained with Hoechst 33342. Panels (F–H) display isotype controls for 
SH-SY5Y (F), LAN-6 (G) and SK-N-BE(2) cells (H). 
The shorter SYK splice variant SYK B has previously been detected in different cell types [5–
7,37]. We observed that SH-SY5Y, LAN-6 and SK-N-FI cells concomitantly express both splice 
variants of SYK mRNA at similar levels whereas SH-EP1, SK-N-SH, and IMR-32 exhibit 
predominantly the short SYK B variant. The monocytic cell lines U937 and THP-1 with known SYK 
expression were used as positive controls for RT-PCR and western blot, respectively [43].  
ICC was used to confirm the presence of SYK protein in SH-SY5Y and LAN-6 cells. A clear SYK 
labeling was observed in the cytoplasm of SH-SY5Y (Figure 2C) and LAN-6 cells (Figure 2D). The 
SYK signal appears to be localized mainly in the cytoplasm, with an increased intensity in patch-like 
structures. However, a faint staining was also observed in SK-N-BE(2) cells (Figure 2E). This could 
most likely be attributed to some moderate non-specific binding of the antibody. No staining was 
apparent in cells incubated with an isotype control antibody (Figure 2F–H).  
2.3. SYK Is Phosphorylated in Neuroblastoma Cell Lines  
SYK activity is tightly controlled by its (auto)phosphorylation and important regulatory 
functions are associated with particular tyrosine residues, such as tyrosine 323, 352, 525, and 526 [8]. 
To determine whether SYK exhibits basic activity in neuroblastoma cell lines, we performed SYK 
immunoprecipitation followed by western blot with different phosphotyrosine-specific SYK 
antibodies in SH-SY5Y cell lysates and THP-1 cells, serving as a positive control. We detected 
phosphorylation of tyrosine 352 and tyrosine 323 in both cell types (Figure 3A).  
The presence of phosphorylated tyrosine 525/526 was examined by immunocytochemistry. 
Phospho-525/526 SYK was detected in the cytoplasm and close to the cell membrane in both SH-SY5Y 
cells (Figure 3B) and LAN-6 cells (Figure 3C). A weak nuclear staining was also noticeable. Variations 
in staining intensity were observed among the cells. As no prior synchronization or stimulation of 
the cells was performed, this may be attributed to the dynamic regulation of SYK-phosphorylation 
[8]. A very weak staining, most probably caused by non-specific background binding of the antibody, 
was observed in SK-N-BE(2) cells (Figure 3D) with no apparent SYK expression (Figure 2A,B). 
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Figure 3. SYK is phosphorylated in neuroblastoma cell lines. (A) Immunoprecipitation with a SYK 
specific antibody was performed followed by western blot using antibodies against the SYK Tyr352 
and Tyr323 phosphorylation residues. THP-1 cells were used as a positive control. 
Immunofluorescence labeling of p-SYK (Tyr525/526) in SH-SY5Y (B) and LAN-6 cells (C). SK-N-BE(2) 
cells (D) served as a negative control. The nuclei (blue) were stained with Hoechst 33342. 
2.4. Downregulation of SYK Reduces the Cell Viability of SYK Expressing Neuroblastoma Cell Lines 
Using siRNA, we assessed the consequences of SYK knockdown on the cell viability of SYK-
positive SH-SY5Y and LAN-6 as well as SK-N-BE(2) cells that show no apparent SYK expression. In 
SH-SY5Y and LAN-6, but not SK-N-BE(2) cells, we observed a significant decrease in cell viability 72 
h post-transfection with two different SYK targeting siRNAs compared to scramble control siRNA 
(scr.) (Figure 4A). The decreased cell viability corresponded to reduced SYK protein levels in 
SH-SY5Y and LAN-6 cells (Figure 4B). Using densitometry, we calculated the downregulation of SYK 
protein. In SH-SY5Y cells the downregulation was approximately 5-fold with 18.1% (siRNA 1) and 
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21.3% (siRNA 2) of SYK protein remaining compared to the scrambled siRNA control (=100%). In 
LAN-6 cell the downregulation was less effective with 45.2% (siRNA 1) and 40.7% (siRNA 2) 
remaining SYK protein compared to the scrambled siRNA control. 
 
Figure 4. SYK downregulation reduces the cell viability of SYK expressing neuroblastoma cell lines. 
SYK-positive SH-SY5Y and LAN-6 cells, as well as SYK-negative SK-N-BE(2) cells, were transfected 
with 5 pmol SYK specific or scrambled (scr.) siRNA. The medium was replaced after 4 h. After 72 h, 
the cell viability was evaluated by MTT assay (A). The scr. control was set as 100% viable cells. Data 
are presented as mean ± SD from three independent experiments. Statistical comparisons were made 
using two-way ANOVA and a significant effect was observed for the siRNA treatment p < 0.001 and 
between cell lines p = 0.003. The Dunnett’s multiple comparison test was used to evaluate the 
difference between scr. siRNA vs. SYK specific siRNA: ** p < 0.01, *** p < 0.001. (B) SYK expression 
levels were determined by western blot. 
2.5. SYK Activity Inhibition Decreases the Cell Viability of Neuroblastoma Cells  
Four commercially available, pharmacological SYK inhibitors were used to evaluate the effect of 
SYK catalytic inhibition on the cell viability of SYK-positive SH-SY5Y and SYK-negative SK-N-BE(2) 
cells. Figure 5 displays the cell viability (MTT assay) after 48 h incubation with the SYK inhibitors 
BAY 61-3606 (Figure 5A), R406 (Figure 5B), PRT062607 (=P505-15; Figure 5C) and GS-9973 
(=entospletinib; Figure 5D). The results of 24 h incubation with these inhibitors are shown in 
Supplementary Figure S3 and comparable tendencies could be observed. A statistically significant 
difference (control vs. treatment) in the cell viability of SH-SY5Y and SK-N-BE(2) cells was observed 
upon exposure to multiple inhibitor concentrations (marked by asterisks in the graphs). SH-SY5Y 
cells expressing high SYK levels were significantly more sensitive to the SYK inhibitors in comparison 
to SK-N-BE(2) cells expressing very low or no SYK (Figure 5). All four inhibitors significantly reduced 
the cell viability of both cell lines in a dose-dependent matter suggesting that at higher inhibitor 
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concentrations the decrease in cell viability of SK-N-BE(2) is SYK-independent and caused by off-
target effects. 
 
Figure 5. Inhibition of SYK decreases the cell viability of neuroblastoma cells. Cell viability was 
measured in SH-SY5Y and SK-N-BE(2) cells by MTT assay after 48 h incubation with increasing 
concentrations of the SYK inhibitors BAY 61-3606 (A) R406 (B) PRT062607 (C) GS-9973 (D). The 
control was set as 100% viable cells. Data are presented as mean ± SD from three independent 
experiments. Using two-way ANOVA, a significant difference between cell lines and a significant 
effect of the inhibitor p < 0.001 was seen. Dunnett’s multiple comparison test was used to evaluate the 
difference between vehicle treated control cells and the various inhibitor concentrations: * p < 0.05 ** 
p < 0.01 *** p < 0.001. 
Considering only inhibitor concentrations that impaired the cell viability of SH-SY5Y but not 
SK-N-BE(2) cells after 48 h of treatment, the concentration ranges were more narrow: 0.01-0.6 μM for 
BAY 61-3606, 0.8–1 μM for R406, and 1 μM for both PRT062607 and GS-9973. Because BAY 61-3606 
displayed the most prominent differences between the two cell lines, it was used in subsequent 
experiments.  
2.6. Inhibition of SYK Activity Reduces ERK1/2 and Akt Phosphorylation in Neuroblastoma Cells 
Active SYK is known to affect various downstream targets including MAPK, PI3K/Akt and 
NFκB signaling pathways [4,8,36]. Hence, we evaluated the consequences of SYK inhibition on 
ERK1/2 and Akt phosphorylation under the same experimental conditions used for the cell viability 
studies. As compared to vehicle alone, a significant and lasting reduction of ERK1/2 phosphorylation 
(Figure 6A,B) and Akt phosphorylation (Figure 6A,C) was observed for three out of four inhibitors 
(BAY 61-3606, R406, and PRT062607) after 4 h and 24 h. In contrast, GS-9973 treatment did not affect 
ERK1/2 or Akt phosphorylation at the investigated time points.  
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Figure 6. SYK inhibition decreases ERK1/2 and Akt phosphorylation. SYK inhibitors BAY 61-3606, 
R406, and PRT062607 reduce the phosphorylation of ERK1/2 and Akt in SH-SY5Y cells after a 4 or 24 
h treatment (A). Control cells were treated with the corresponding vehicles (water = vehicle control 1 
and DMSO = vehicle control 2). Densitometric analysis of the protein bands was performed. 
Phosphorylated and total protein were normalized to their respective GAPDH loading controls and 
the ratios between normalized p-ERK1/2 and ERK as well as normalized p-Akt and Akt were 
calculated. The values are displayed as mean ± SD relative to the vehicle control = 1 (B and C). The 
results are based on three independent experiments. One sample t-test (two-tailed) was performed to 
compare the vehicle (theoretical mean = 1) vs. inhibitor treatment: * p < 0.05 ** p < 0.01 *** p < 0.001. 
2.7. The Selective SYK Inhibitor BAY 61-3606 Enhances the Effect of Chemotherapeutic Drugs on 
Neuroblastoma Cells 
To determine whether SYK inhibition could increase the efficacy of chemotherapeutic agents to 
inhibit neuroblastoma cell growth, we combined BAY 61-3606 with the drugs paclitaxel, cisplatin, 
doxorubicin, and temozolomide, respectively. We investigated the effect of single vs. combined 
treatment on PARP cleavage (indicating apoptosis) and cell viability (MTT assay) in SYK-positive 
SH-SY5Y and SYK-negative SK-N-BE(2) cells (Figure 7A and Table 2). After 24 h, we observed an 
increase in cleaved PARP in SH-SY5Y cells for the combination of 0.4 μM BAY 61-3606 with paclitaxel, 
cisplatin, and temozolomide compared to single drug treatment (Figure 7A). For the combination of 
0.4 μM BAY 61-3606 with paclitaxel or cisplatin this effect was sustained after 48 h (Supplementary 
Figure S4A). 
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Of note, after 24 h incubation with BAY 61-3606, paclitaxel or the combination temozolomide-
BAY 61-3606 increased SYK protein levels could be observed (Figure 7A). This effect was not 
sustained after 48 h (Supplementary Figure S4A). However, after 48 h a clear reduction in SYK protein 
levels could be detected in cells treated with a combination of BAY 61-3606 and chemotherapeutic 
drugs compared to treatment with drugs alone (Supplementary Figure S4A).  
After 48 and 72 h incubation, a significant decrease in cell viability was evident for all drugs in 
combination with BAY 61-3606 in SH-SY5Y cells as compared to the chemotherapeutic drugs alone 
(Table 2). 
In SK-N-BE(2) cells the apparent increase in cleaved PARP after combined treatment with BAY 
61-3606 and paclitaxel was accompanied by a decrease in cell viability after 48 h and 72 h (Table 2). 
Comparing the combinations to treatment with BAY 61-3606 alone, a significant difference was 
observed for paclitaxel and cisplatin but not doxorubicin and temozolomide after 48 h and 72 h in 
SH-SY5Y cells, indicating that monotherapy with 0.4 μM BAY 61-3606 is comparable to a combination 
of temozolomide or doxorubicin and BAY 61-3606.  
 
Figure 7. The selective SYK inhibitor BAY 61-3606 enhances the effect of chemotherapeutic drugs in 
neuroblastoma cells. (A) PARP cleavage and SYK expression were determined by western blot after 
24 h monotherapy or combinations of 0.4 µM BAY 61-3606, 20 nM paclitaxel, 5 nM doxorubicin, 100 
µM temozolomide and cisplatin (1 µM or 3 µM for SH-SY5Y and SK-N-BE(2), respectively). 
Illustration of drug combination effects for 0.4 µM BAY 61-3606 and paclitaxel (B) as well as 0.4 µM 
BAY 61-3606 and cisplatin (C) in SH-SY5Y and SK-N-BE(2) cells after 48 h and 72 h treatment. The 
continuous horizontal line indicates the effect of the highest single agent, the dashed line denotes 
expected additive effect calculated by the Bliss independence model, and the dotted line shows 
expected additive effect calculated by response additivity. Combination index (CI), given from the 
Bliss independence model and the response additivity, and effect are specified for each combination. 
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Table 2. Cell viability of SH-SY5Y and SK-N-BE(2) after treatment with 0.4 μM BAY 61-3606, chemotherapeutic drugs or combinations of both. 
 
 SH-SY5Y SK-N-BE(2) 
Treatment 
Cell viability (%) 







Cell viability (%) 








0.4 μM BAY 79.01 ± 6.26   94.04 ± 7.72   
Paclitaxel 87.71 ± 7.83   90.89 ± 7.86   
Paclitaxel + BAY 54.65 ± 3.26 <0.001 <0.001 72.98 ± 9.33 <0.001 <0.001 
Cisplatin 82.33 ± 9.01   98.94 ± 6.48   
Cisplatin + BAY 62.47 ± 5.82 <0.001 <0.001 90.49 ± 7.46 0.052 >0.999 
Doxorubicin 100.5 ± 9.59   102 ± 9.68   
Doxorubicin + BAY 77.97 ± 8.01 <0.001 >0.999 93.69 ± 8.78 0.121 >0.999 
Temozolomide 107 ± 11.17   107.7 ± 3.65   
Temozolomide + BAY 76.81 ± 4.82 <0.001 >0.999 100 ± 4.36 0.132 0.181 
72 h 
0.4 μM BAY 80.20 ± 7.62   96.97 ± 6.89   
Paclitaxel 84.53 ± 4.60   88.29 ± 5.19   
Paclitaxel + BAY 36.79 ± 3.14 <0.001 <0.001 59.48 ± 8.81 <0.001 <0.001 
Cisplatin 73.38 ± 5.89   73.99 ± 2.95   
Cisplatin + BAY 56.25 ± 5.72 <0.001 <0.001 73.53 ± 5.94 >0.999 <0.001 
Doxorubicin 102.2 ± 8.37   101.3 ± 7.56   
Doxorubicin + BAY 78.57 ± 7.16 <0.001 >0.999 93.99 ± 9.68 0.053 >0.999 
Temozolomide 107.7 ± 6.13   102.7 ± 4.28   
Temozolomide + BAY 74.21 ± 5.99 <0.001 0.217 99.74 ± 6.68 >0.999 >0.999 
Cell viability was measured by MTT assay after 48 and 72 h. The control was set as 100% viable cells. Data are presented as mean ± SD from at least three independent 
experiments. Using two-way ANOVA, a significant effect was observed for both treatment and between cell lines p < 0.001; Bonferroni’s multiple comparison test 
was used to evaluate differences between treatments, and p values < 0.05 were considered as statistically significant.
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Using Bliss independence and response additivity calculations, we determined whether the 
chemotherapeutic drug-BAY 61-3606 combination was synergistic, additive or antagonistic in regard 
to cell viability. The combinations of BAY 61-3606 and doxorubicin or temozolomide could not be 
analyzed with these methods due to the limited effects of these drugs as single agents at 
concentrations used in this study. A synergistic effect was determined for paclitaxel in combination 
with BAY 61-3606 in both SH-SY5Y and SK-N-BE(2) cells after 48 and 72 h (Figure 7B). Additionally, 
cisplatin in combination with BAY 61-3606 displayed a mainly additive effect in SH-SY5Y and 
SK-N-BE(2) cells after 48 and 72 h (Figure 7C). 
A 24 h treatment with a higher BAY 61-3606 concentration (0.8 μM) in combination with any of 
the drugs resulted in a more pronounced increase in cleaved PARP in SH-SY5Y cells but not in the 
SYK-negative SK-N-BE(2) cells (Supplementary Figure S5A) after 24 h. However, after 48 h higher 
levels of PARP were observed in the combinations compared to treatment with chemotherapeutic 
drugs alone for the majority of drugs in SH-SY5Y and to a lesser extent in SK-N-BE(2) cells 
(Supplementary Figure S4B). Furthermore, a significant decrease in cell viability was observed for 
both cell lines comparing chemotherapeutic drug vs. combination with BAY 61-3606 after 48 and 72 h 
(Supplementary Table S2). However, when comparing the combinations to treatment with BAY 
61-3606 alone, a significant difference in cell viability occurred for combinations of BAY 61-3606 with 
paclitaxel, cisplatin and temozolomide in SH-SY5Y cells after 48 h, and paclitaxel as well as cisplatin 
after 72 h. In SYK-negative SK-N-BE(2) cells combination of paclitaxel, cisplatin or doxorubicin and 
BAY 61-3606 after 72 h and paclitaxel as well as cisplatin after 48 h demonstrated a significant 
difference compared to monotherapy with BAY 61-3606. 
A synergistic effect was determined for paclitaxel in combination with 0.8 μM BAY 61-3606 in 
both SH-SY5Y and SK-N-BE(2) cells after 48 and 72 h (Supplementary Figure S5B). Additionally, 
cisplatin in combination with 0.8 μM BAY 61-3606 displayed a less consistent effect, the 
combinational effects were mainly additive in SH-SY5Y and SK-N-BE(2) cells after 48 and 72 h 
(Supplementary Figure S5C) but some of the combinations were classified as synergistic or 
antagonistic using Bliss independence and response additivity calculations.  
2.8. Transfection with an Active SYK Variant Increases the Cell Viability of Neuroblastoma Cells 
Independent of Endogenous SYK Levels 
To further explore the effect of SYK on neuroblastoma cell viability, we transfected SH-SY5Y, 
SK-N-BE(2), and SK-N-AS cells with expression vectors encoding different FLAG-tagged SYK 
variants (SYK wt = SYK wild type, SYK B = short SYK splice variant B, SYK Y130E = constitutive active 
SYK, SYK K402R = kinase dead SYK, SYK RR42/195KK = SYK with inactive SH2 domains). After 48 
h, we measured the cell viability and confirmed transfection efficiency by evaluating exogenous SYK 
expression levels using western blot (Figure 8). SYK overexpression that exceeded the endogenous 
SYK levels was evident. Constitutive active SYK Y130E increased cell viability of all three 
neuroblastoma cell lines in comparison to transfection with the empty vector independent of the 
presence/absence of endogenous SYK (Figure 8A). Transfection with SYK wt significantly increased 
the cell viability of SK-N-AS cells and SYK RR42/195KK increased the cell viability of SH-SY5Y cells. 
A minor, reproducible reduction in cell viability after transfection with the kinase dead SYK mutant 
was observed in SH-SY5Y and SK-N-BE(2) cells, which was however not statistically significant. 
Following transfection, all SYK variants were detected in the three cell lines by western blot 
although SYK RR42/195K was expressed at somewhat lower levels (Figure 8B). 
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Figure 8. Transfection with an active SYK variant increases the cell viability of neuroblastoma cells 
independent of endogenous SYK levels. Cells were transfected with expression plasmids encoding 
different SYK variants and the cell viability was measured after 48 h by MTT assay (A). The empty 
vector control was set as 100% viable cells. Data are presented as mean ± SD from six independent 
experiments. Statistical comparisons were made using two-way ANOVA and a difference was 
observed between the SYK variants and between cell lines p < 0.001. The Dunnett’s multiple 
comparison test was used to evaluate the difference between empty vector and different SYK variants: 
* p < 0.05, *** p <0.001. Western blot analysis was used to evaluate the presence of SYK following 
transfection, ensuring sufficient transfection efficiency (B). SYK wt = SYK wild type, SYK B = short 
SYK splice variant B, SYK Y130E = constitutive active SYK, SYK K402R = kinase dead SYK, SYK 
RR42/195KK = SYK with inactive SH2 domains. 
3. Discussion 
There is a need for further advancements in the treatment of neuroblastoma to improve the 
survival of high-risk patients and reduce acute and long-term toxic effects in neuroblastoma 
survivors. Targeted therapies exhibit great potential used either alone or more particularly in 
combination with conventional drugs [41,44].  
In two other pediatric cancers, retinoblastoma and Ewing sarcoma, SYK promotes tumor cell 
survival and SYK inhibition, using small molecule inhibitors, was identified as a promising treatment 
option for these diseases [35,36]. 
In the present study, we observed that SYK expression was higher in four different 
neuroblastoma cohorts compared to neural crest cells and benign neurofibroma. Moreover, we 
demonstrate that SYK is present in neuroblastoma tissues and to a lesser extent in neuroblastoma cell 
lines. Inhibition of SYK using small molecule inhibitors alone or in combination with 
chemotherapeutic drugs as well as knockdown of SYK by siRNA impaired the cell viability of SYK 
expressing neuroblastoma cells. Additionally, SYK inhibition decreased phosphorylation of Akt and 
ERK1/2 indicating Akt and MAPK signaling as potential downstream targets of SYK in 
neuroblastoma. Furthermore, constitutive active SYK increased neuroblastoma cell viability 
independent of endogenous SYK expression. Taken together, our findings indicate a tumorigenic 
involvement of SYK in neuroblastoma. 
We observed the presence of SYK protein in the majority of neuroblastoma tissues analyzed in 
this study. A positive staining of SYK and p-SYK was observed in both the cytoplasm and the nucleus 
with a more pronounced nuclear staining for p-SYK. The presence of SYK in different cellular 
compartments (cytoplasm, nucleus, membrane) has previously been described [37,45,46]. 
Furthermore, we compared the presence of SYK protein in MYCN-amplified and non-MYCN-
amplified tumor tissue and did not observe differences between the two groups. Of note, by 
examining publicly available gene expression datasets, we detected a negative correlation between 
MYCN and SYK in neuroblastoma. In contrast, a positive correlation between SYK and MYC was 
discerned. MYCN-amplification occurs in about 20% of neuroblastomas and is associated with 
aggressive tumors and poor survival [47–49]. Furthermore, MYC has also been identified as an 
independent prognostic marker for poor survival in neuroblastoma [50] and is predominantly 
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expressed by non-MYCN-amplified tumors [51]. A link between SYK and MYC has been previously 
demonstrated in Ewing sarcoma and hematopoietic cells [36,52]. Therefore, a potential connection 
between SYK and MYC in neuroblastoma is highly interesting and warrants further investigation.  
In contrast to neuroblastoma tumor tissue, SYK protein was only detected in two out of ten 
neuroblastoma cell lines by western blot. This is in accordance with previous findings by Alaminos 
et al. reporting more frequent methylation of the SYK promoter in neuroblastoma cell lines (60%) 
compared to tumor tissue (11%) [53]. In subsequent work by Margetts et al. and Grau et al. no 
aberrant hypermethylation of the SYK promoter was observed in tumor tissue or highly infiltrated 
bone marrow [54–56]. Yu et al. recently demonstrated that EGF stimulates SYK-mediated migration 
and invasion in ovarian cancer cells. The authors suggested that SYK function might be regulated by 
environmental stimuli [11]. Therefore, one could speculate that the absence of a specific stimulus, 
which is present in the tumor microenvironment, could lead to the downregulation of SYK expression 
in neuroblastoma cells lines. However, additional studies are necessary to determine if known 
factors, such as specific cytokines and chemokines, present in the neuroblastoma tumor 
microenvironment may affect SYK expression and function. 
Complex phosphorylation events on tyrosine residues are required for the regulation of SYK 
functions by mediating conformational changes and creating docking stations for other proteins 
[8,57,58]. Phosphorylation of Tyr352 and/or Tyr348 (Tyr346 and Tyr342 in mouse SYK) provides 
binding sites for various proteins such as phospholipase Cγ, Vav-1 and 2 as well as Akt, and ERK, 
linking SYK to different signaling pathways and cellular functions [8,59–62]. Furthermore, Tyr352 
has been linked to constitutive SYK activation [63]. The Tyr525/526 residues are located in the SYK 
activation loop. These phosphorylation sites likely provide important docking sites for other proteins 
thereby mediating intracellular signaling. However, mutations in these sites affect the in vitro 
catalytic activity only marginally [8,64,65]. Phosphorylation of Tyr323 in SYK promotes binding of 
Cbl protein family members causing ubiquitination and possibly degradation of SYK. However, 
Tyr323 is also an important binding site for PI3K indicating multiple functions of this 
phosphorylation site (reviewed in [8]).  
We determined the status of these three well-established SYK phosphorylation sites (Tyr352, 
Tyr525/526, and Tyr323) and found that all were phosphorylated under normal growth conditions in 
the SYK expressing SH-SY5Y neuroblastoma cells, suggesting the presence of catalytically active SYK.  
We observed a weaker nuclear staining of both total SYK and p-SYK in neuroblastoma cell lines 
as compared to neuroblastoma tissue. It has previously been demonstrated that SYK splice variants 
display differences in cellular localization and function [37,66,67] and that EGF can modulate SYK 
splicing pattern [66]. These findings indicate that the cellular localization of SYK may be affected by 
environmental stimuli and changes in splicing pattern. Therefore, the presence of specific stimuli in 
the neuroblastoma tumor microenvironment as well potential differences/changes in SYK splicing 
pattern compared to neuroblastoma cell lines may contribute to the observed differences in staining 
pattern. In our study, we observed that siRNA-mediated SYK downregulation reduced 
neuroblastoma cell growth. However, we did not achieve a complete SYK knockdown. Since SYK is 
a protein kinase, residual SYK protein could provide an explanation for the significant, but modest 
effect on the cell viability. 
Therefore, we investigated the effects of commercially available SYK inhibitors BAY 61-3606 
[68], R406 [69], PRT062607 (P505-15) [70] and GS-9973 [71] on neuroblastoma survival. Using 
increasing inhibitor concentrations, we compared the effect on cell viability in neuroblastoma cells 
with and without detectable SYK protein levels (SH-SY5Y and SK-N-BE(2), respectively). We 
determined at least one concentration for each inhibitor at which a significant reduction in cell 
viability was observed in SH-SY5Y but not SK-N-BE(2) cells, indicating an effect on cell viability that 
can likely be attributed to specific SYK inhibition. 
PRT062607 and GS-9973 significantly reduced the viability of SH-SY5Y but not SK-N-BE(2) cells 
at a concentration of 1 μM. This is in line with recent work by Sun et al. where 1 μM PRT062607 and 
GS-9973 significantly impaired clonogenicity and cell viability of Ewing sarcoma cell lines [36]. A 
dose-dependent impairment of cell viability as well as increased caspase-3 activity has been 
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previously reported in retinoblastoma cells after treatment with BAY 61-3606 and R406 [35]. We 
observed that these inhibitors significantly decreased SH-SY5Y cell viability as compared to 
SK-N-BE(2) cells at concentrations of 0.1–0.6 μM and 0.8–1 μM, respectively. 
Of note, inhibitor concentrations >1 μM also significantly reduced the cell viability of SK-N-BE(2) 
cells that exhibit no apparent SYK expression suggesting off-target effects for all four inhibitors when 
used at higher concentrations. Kinase inhibitors commonly display off-target effects that can be 
beneficial but need to be carefully evaluated at the mechanistic level. For example, the SYK inhibitor 
BAY 61-3606 has been reported to inhibit JNK [72]. JNK inhibition has previously been demonstrated 
to reduce the apoptotic effect of chemotherapeutic drugs such as doxorubicin in SH-SY5Y cells [73]. 
Therefore, off-target effects of BAY 61-3606 on JNK could potentially impair doxorubicin function 
and not display a potentiating effect as seen in our studies. Furthermore, work by Colado et al. 
demonstrated that GS-9973 and R406 can impair T-cell function via off-target effects on the SYK 
homolog ZAP-70 [74]. We screened the neuroblastoma cell lines used in this study for ZAP-70 
presence and found it expressed at protein level only in SK-N-DZ cells (Supplementary Figure S6). 
Since this cell line was not used in the inhibitor studies, potential off-target effects on ZAP-70 can be 
excluded. However, these are just two of many potential proteins that may be the target of non-
selective inhibition. 
Various downstream targets for SYK have been described in health and disease [4,8]. ERK- and 
Akt-mediated signaling is known to be affected by SYK inhibition in CLL and Ewing sarcoma [20,36]. 
We observed that Akt and ERK1/2 phosphorylation was decreased by the SYK inhibitors BAY 
61-3606, R406 and PRT062607, but not GS-9973. A possible explanation could be differences in the 
kinetics of GS-9973 mediated SYK inhibition. Since we only examined two time points, (4 h and 24 h) 
rapid and transient effects might not have been detected. PI3K/Akt- and MAPK-mediated signaling 
was previously shown to promote neuroblastoma tumorigenesis [75–79]. Therefore, a decrease in Akt 
and ERK1/2 phosphorylation and activity could contribute to the impaired cell viability. 
Yu et al. demonstrated an increased expression of SYK in paclitaxel-resistant ovarian cancer cells 
and that paclitaxel in combination with the SYK inhibitor R406 increased apoptosis in vitro and 
impaired tumor growth in vivo [33]. Paclitaxel is a chemotherapeutic drug that is rarely used for the 
treatment of neuroblastoma. It was, however, included in this study to determine if the additive effect 
seen in ovarian cancer cells [33] could also be observed in neuroblastoma cell lines. We furthermore 
analyzed the effect of three drugs used in first-line treatment and/or refractory and relapsed 
neuroblastoma: cisplatin, doxorubicin, and temozolomide.  
We compared the cell viability of neuroblastoma cells treated with cytostatic drugs alone or in 
combination with the pharmacological SYK inhibitor BAY 61-3606. Synergetic and additive effects 
were observed in SYK expressing SH-SY5Y cells for paclitaxel- BAY 61-3606 and cisplatin- BAY 
61-3606 combination, respectively. Furthermore, 0.4 μM BAY 61-3606 potentiated the effects of 
doxorubicin and temozolomide in SH-SY5Y cells. Interestingly, a synergetic effect of BAY 61-3606 in 
combination with paclitaxel was also observed in SK-N-BE(2), a cell line without significant 
expression of SYK protein. Although BAY 61-3606 concentrations applied in this study are rather 
low, off-target effects are likely the cause for the observed effect. 
Furthermore, we observed increased amounts of cleaved PARP in the SYK-positive SH-SY5Y 
cells after treatment with BAY 61-3606 (0.4 and 0.8 μM) in combination with the tested drugs after 24 
h, particularly when 0.8 μM BAY 61-3606 was used. We propose that the decrease in cell viability in 
SH-SY5Y cells may be attributed to an increase in apoptosis, whereas the decrease in cell viability in 
SYK-negative SK-N-BE(2) cells might rather be due to reduced proliferation than increased apoptosis. 
However, further experiments are required to determine the detailed mechanisms. 
In addition, we also demonstrate that transient transfection with a constitutively active SYK 
variant increased the cell viability of neuroblastoma cell lines independent of endogenous SYK 
expression. This suggests that SYK has tumor-promoting functions in neuroblastoma. Previous work 
reported a tumor-suppressing role for SYK in breast cancer, among others. Transfection of breast 
cancer cells with a wild-type SYK encoding vector suppressed invasive outgrowth in Matrigel and 
impaired tumor growth and metastasis in mice [26]. We did, however, not observe any inhibitory 
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effect on the cell viability of transfected neuroblastoma cell lines expressing exogenous SYK. Taken 
together, this suggests that SYK functions as a tumor-promoting molecule in neuroblastoma rather 
than having a tumor-suppressing effect.  
To further evaluate the potential therapeutic use of SYK inhibitors in neuroblastoma both as a 
single agent and in combination with existing chemotherapeutic drugs, in vivo studies are necessary. 
Since SYK is widely expressed by hematopoietic cells, potential negative effects on the immune cells 
of the tumor microenvironment have to be carefully evaluated using immunocompetent 
neuroblastoma animal models. Recent work in glioma demonstrated that SYK inhibition impaired 
the mobility and infiltration of B cells and CD11b+ leukocytes in addition to reducing proliferation 
and migration of tumor cells [34]. 
4. Materials and Methods  
4.1. Microarray Gene Expression  
Gene expression analysis was performed using the MegaSampler feature of the publicly 
available R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl). 
4.2. Reagents and Antibodies 
The selective SYK inhibitors GS-9973 (Entospletinib) and R406 were purchased from Selleck 
Chemicals Europe (Munich, Germany). BAY 61-3606 and PRT062607 were obtained from 
Calbiochem/Merck (Merck Life Science AS, Oslo, Norway) and ApexBio (Houston, TX, USA), 
respectively. Paclitaxel, cisplatin, doxorubicin, and temozolomide were bought from Sigma-Aldrich 
Norway AS (Oslo, Norway). The antibodies used in this study are listed in Table 3. 
Table 3. Antibodies. 
Antibody Application Source 
Anti-SYK WB, IP #1240, Santa Cruz Biotechnology 
Anti-SYK WB #13198, Cell Signaling Technology 
Anti-SYK ICC/IHC #HPA001384, Sigma 
Anti-Phospho-ZAP-70 (Tyr319)/ 
SYK (Tyr352) 
WB #2701, Cell Signaling Technology 
Anti-Phospho-SYK (Tyr323) WB #2715, Cell Signaling Technology 
Anti-Phospho-SYK (Tyr525/526) ICC #2710, Cell Signaling Technology 
Anti-Phospho-SYK (pTyr525) IHC #SAB4503839, Sigma 
Anti-PARP WB #9542, Cell Signaling Technology 
Anti-Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) WB #4370, Cell Signaling Technology 
Anti-p44/42 MAPK (Erk1/2) WB #4695, Cell Signaling Technology 
Anti-Phospho-Akt (Ser473) (D9E) WB #4060, Cell Signaling Technology 
Anti-Akt WB #9272, Cell Signaling Technology 
Anti-GAPDH WB #47724, Santa Cruz Biotechnology 
Goat Anti-Rabbit IgG H&L (HRP) WB #6721, Abcam 
Rabbit Anti-Mouse IgG H&L (HRP) WB #97046, Abcam 
Goat anti-Rabbit IgG (H+L), Alexa Fluor 488 ICC # A-11008, Thermo Fisher Scientific 
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4.3. Human Tissue Samples and Cell Lines 
Human tissue samples were obtained, with informed consent (written or verbal) provided by 
the parents or guardians for the use of tumor samples in research, in accordance with the ethical 
approval from the Stockholm Regional Ethical Review Board and the Karolinska University Hospital 
Research Ethics Committee (approval ID 2009/1369-31/1 and 03-736). Neuroblastoma tumor tissue 
was collected at the Karolinska University Hospital, snap-frozen in liquid nitrogen and stored at −80 
°C until further use. 
The human cell lines SK-N-AS, SK-N-SH, SK-N-DZ, SK-N-FI, SH-EP1, Kelly, SH-SY5Y, and 
IMR-32 as well as THP-1, Jurkat E6.1, and U937 cells were obtained from the ATCC (American Type 
Culture Collection, LGC Standards GmbH, Wesel, Germany). SK-N-BE(2) cells were purchased from 
DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany). The 
cell lines were cultivated in RPMI-1640 medium containing L-glutamine and sodium bicarbonate 
(Sigma-Aldrich Norway AS, Oslo, Norway) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS; Thermo Fisher Scientific Inc., Waltham, MA, USA). LAN-6 cells were a kind gift from 
Deborah Tweddle, Newcastle University and were grown in Iscove’s Modified Dulbecco’s Medium 
(Sigma-Aldrich Norway AS, Oslo, Norway) supplemented with GlutaMAX™ and 10% heat-
inactivated FBS. All cell lines were cultivated at 37 °C in humidified air with 5% CO2 and mycoplasma 
tests were performed regularly using the MycoAlert™ PLUS Mycoplasma Detection Kit (Lonza, 
Basel, Switzerland). The identity of the human neuroblastoma cell lines was confirmed by STR-
profiling performed at the Centre of Forensic Genetics, University of Tromsø, Norway.  
4.4. Immunohistochemistry (IHC) 
Formalin-fixed, paraffin-embedded tissue sections were deparaffinized using xylene (VWR 
International, Oslo, Norway) and a series of graded alcohols (Sigma-Aldrich Norway AS, Oslo, 
Norway) followed by rehydration and washing in phosphate buffered saline (PBS, Biochrom GmbH, 
Berlin, Germany). Antigen retrieval was performed in sodium citrate buffer (pH 6) in a microwave 
oven. After blocking of endogenous peroxidase with 0.3% H2O2 for 15 min, unspecific antibody 
binding sites were blocked with 5% BSA in PBS (AppliChem, Darmstadt, Germany) for 45 min. The 
sections were incubated with the primary antibody overnight at 4 °C. The following day sections 
were thoroughly washed in PBS and incubated with SignalStain®  Boost IHC Detection Reagent, 
HRP, Rabbit (Cell Signaling Technology, Leiden, Netherlands) and kept for 1 h at room temperature. 
Following washes in PBS, the sections were incubated with Liquid DAB+ Substrate solution (Dako, 
Agilent Technologies, Inc., Santa Clara, CA, USA). A matched isotype control was used as a control 
for nonspecific staining. The sections were examined with a BX43 microscope (Olympus, Tokyo, 
Japan) and images were acquired with an Olympus DP26 camera. 
4.5. RNA Isolation and RT-PCR 
Total RNA was isolated using the NucleoSpin®  TriPrep Kit (MACHEREY-NAGEL GmbH & Co. 
KG, Düren, Germany) and RNA quantity and quality was determined with a NanoDrop™ 2000 
spectrometer (Thermo Fisher Scientific Inc.). One μg RNA was used as input for cDNA synthesis 
with the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories AB, Oslo, Norway). 
PCR was set up as a 25 μl reaction mix containing 2 μL cDNA, 12.5 μL AccuStart™ II GelTrack 
PCR SuperMix (Quanta Biosciences, Gaithersburg, MD, USA), 400 nM of each primer (Sigma-Aldrich 
Norway AS, Oslo, Norway) and 10.1 μL of ultra-pure H2O (Biochrom GmbH, Berlin, Germany). The 
PCR run was performed in a T100™ Thermal Cycler (Bio-Rad Laboratories AB) as follows: 2 min at 
94 °C and 35 cycles of 94 °C for 20 s, 61 °C for 30 s and 72 °C for 90 s. The following intron spanning 
primer sets were used: APRT (housekeeping) 5’ CCCGAGGCTTCCTCTTTGGC 3’ (sense) and 5’ 
CTCCCTGCCCTTAAGCGAGG-3’ (antisense) [80], SYK 5’ CATGTCAAGGATAAGAACATCAT 
AGA 3’ (sense) and 5’ AGTTCACCACGTCATAGTAGTAATT 3’ (antisense) [26], SYK L/S 5’ 
TTTTGGAGGCCGTCCACAAC ‘3 (sense) and 5’ ATGGGTAGGGCTTCTCTCTG 3’ (antisense) [37]. 
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All primer sets used in this study were intron-spanning to avoid false positive signals caused by 
amplification of residual traces of genomic DNA. PCR products were analyzed by gel electrophoresis. 
The 2% SeaKem® LE Agarose gel (Lonza) was stained with GelRed™ (Biotium, Inc., Hayward, CA, 
USA) and visualized under UV light in the BioDoc-It™ Imaging System (UVP, LLC, Upland, CA, 
USA). 
4.6. Immunocytochemistry (ICC) and Western Blot 
Cells were grown in 8-well µ-Slide dishes (iBidi GmbH, Munich, Germany) until they reached 
approximately 70% confluence. Following a brief rinse with PBS the cells were fixed with 4% 
formaldehyde (Alfa Aesar, VWR International, Oslo, Norway) for 20 min. After three washes with 
PBS, unspecific binding sites were blocked with 5% goat serum (Sigma-Aldrich Norway AS) in PBS 
containing 0.3% Triton-X-100 (Sigma-Aldrich Norway AS) for 1 h. The cells were incubated with 
primary antibodies diluted in 1% bovine serum albumin (BSA; AppliChem, Darmstadt, Germany) in 
PBS containing 0.3% Triton-X-100 overnight at 4 °C. After three washes with PBS, the cells were 
incubated with the secondary antibodies diluted in 1% bovine serum albumin in PBS containing 0.3% 
Triton-X-100 for 1 h at room temperature, protected from light. Following three washes with PBS, the 
nuclei were stained with Hoechst 33342 (ImmunoChemistry Technologies, LLC, Bloomington, IN, 
USA) for 10 min. The cells were washed 3x with PBS and covered with Mounting Medium for 
fluorescence microscopy (iBidi GmbH). Subsequently, the cells were examined using a Zeiss LSM780 
confocal microscope (Carl Zeiss AG, Oberkochen, Germany). Images were taken with the same 
microscope settings (laser intensity, gain etc.) and identical image processing parameters were 
applied to allow comparison between the cell lines. Western blots were performed as previously 
described [81]. 
4.7. Immunoprecipitation (IP) 
Cells were washed twice with cold PBS and lysed by addition of lysis buffer containing 50 mM 
Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% Triton X-100, 1 mM DTT and 1 mM EDTA (Sigma-Aldrich 
Norway AS, Oslo, Norway) as well Halt™ Protease and Phosphatase Inhibitor Cocktail (Thermo 
Fisher Scientific Inc.). Following sonication and centrifugation, the protein concentration was 
determined using a Protein Quantification Assay (MACHEREY-NAGEL GmbH & Co. KG). A sample 
of the supernatant was taken as “input control”, supplemented with NuPAGE®  LDS Sample Buffer 
(4X) (Thermo Fisher Scientific Inc.) as well as 100 mM DTT (AppliChem, Darmstadt, Germany) and 
incubated for 10 min at 70 °C. Cell lysate containing approximately 800 μg protein was pre-cleared 
with an irrelevant IgG2a antibody (same class as the SYK antibody used for IP) to reduce unspecific 
binding. Afterwards, the samples were incubated with the anti-SYK antibody (1 μg) rotating at 4 °C 
overnight followed by incubation with 80 μl of a 50% Sepharose G beads/lysis buffer solution (GE 
Healthcare, Oslo, Norway) for 1 h rotating at 4 °C. The beads were washed three times with lysis 
buffer and two times with 50 mM Tris-HCl, pH 8.0. Afterwards, the beads were incubated in sample 
buffer containing NuPAGE®  LDS Sample Buffer (4×), ultrapure H2O as well as 100 mM DTT for 10 
min at 70 °C. The samples were subsequently used for western blot analysis. 
4.8. siRNA-mediated SYK silencing 
Two pre-designed SYK siRNAs were used in this study: ID-s13679 (siRNA 1) and ID-s13681 
(siRNA 2) as well as a scramble control #1 siRNA (cat# 4392420 and 4390843, Ambion, Thermo Fisher 
Scientific Inc.). Cells were seeded into 24- and 6-well plates for cell viability assay and western blot 
analysis, respectively. After 24 h, the cells were transfected with the different siRNAs using 
Lipofectamine RNAiMAX reagent (Thermo Fisher Scientific Inc.) according to the manufacturer’s 
specifications. Briefly, cells were incubated with 5 pmol (24-well plate) or 30 pmol siRNA (6-well 
plate) per well in Opti-MEM (Thermo Fisher Scientific Inc.) for 4 h followed by the removal of the 
transfection mix and addition of fresh Opti-MEM. After 72 h the cell viability was assessed and cells 
were harvested for western blot analysis. Densitometry was performed using Fiji software [82]. 
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4.9. Cell Viability Assay 
To assess the effect of the commercially available SYK inhibitors BAY 61-3606, R406, GS-9973 
(Entospletinib) and PRT062607 alone as well as BAY61-3606 in combination with paclitaxel, cisplatin, 
doxorubicin and temozolomide on the cell viability of SH-SY5Y and SK-N-BE(2) neuroblastoma cells 
the colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazodium bromide)-assay was 
used [83]. The cells were seeded in 96-well plates in full growth media. As an exception, cells treated 
with GS-9973 and PRT062607 were seeded in Opti-MEM to reduce cell viability variations attributed 
to residual serum. After 24 h, the cells were washed once with Opti-MEM before incubation with SYK 
inhibitors alone for 24 and 48 h or a combination of chemotherapeutic drugs with BAY61-3606 for 48 
and 72 h. Control cells received the corresponding drug vehicle at the highest concentration present 
in the drug-treated cells. BAY 61-3606 and doxorubicin were dissolved in water, R406, GS-9973, 
PRT062607, and temozolomide in DMSO, paclitaxel in ethanol, and cisplatin in 0.9% saline. After 24, 
48 or 72 h the MTT solution (10 μL of 5 mg MTT, Sigma-Aldrich Norway AS, per ml phosphate 
buffered saline) was added to each well and incubated for additional 3 h. To facilitate formazan 
crystal solubilizing, 70 μL of the solution were carefully removed from each well, 100 μL isopropanol 
containing 0.04 M HCl were added and mixed thoroughly. In addition, the plates were placed on an 
orbital shaker for 1 h at room temperature. The absorbance was measured with a CLARIOstar plate 
reader (BMG LABTECH, Ortenberg, Germany) at 590 nm. The experiment was performed at least 
three times with at least three parallels per treatment. The cell viability was calculated as the ratio of 
the mean OD of treated cells over vehicle treated control cells (100% living cells). The cell viability 
assay for the siRNA and SYK plasmid studies were performed in 24-well plates. The amounts of MTT 
solution and acidic isopropanol were adjusted correspondingly. 
4.10. Cell Signaling Study 
To investigate the effect of commercially available SYK inhibitors on MAPK- and Akt- mediated 
signaling SH-SY5Y cells were seeded in 6-well plates in full growth medium. The next day, the cells 
were washed in Opti-MEM and treated with BAY 61-3606, R406, GS-9973 (entospletinib), PRT062607 
or corresponding vehicle controls (water for BAY 61-3606 and DMSO for R406, GS-9973, and 
PRT062607) for 4 or 24 h. Following incubation, the cells were washed with PBS and harvested in 
RIPA Lysis and Extraction Buffer containing Halt™ Protease and Phosphatase Inhibitor Cocktail 
(Thermo Fisher Scientific Inc.) and analyzed by western blot. Densitometry was performed using Fiji 
software. Phosphorylated and total protein were normalized to their respective GAPDH loading 
control (pERK/GAPDH, ERK/GAPDH, pAkt/GAPDH, Akt/GAPDH). Ratios of pERK/ERK and 
pAkt/Akt were calculated using the normalized values. The respective vehicle control was set as 1 
and the ratios were calculated. 
4.11. Transfection with SYK Plasmids 
The following, previously described FLAG-tagged plasmids were used in this study: pCAF1 
empty expression vector, SYK wt = SYK wild type, SYK B = short SYK splice variant B, SYK Y130E = 
constitutive active SYK, SYK K402R = kinase dead SYK, SYK RR42/195KK = SYK with inactive SH2 
domains [26,46]. Cells were seeded in 24- (cell viability assay) or 6-well plates (western blot) in full 
growth media. The following day the cells were transfected using jetPRIME®  transfection reagent 
(Polyplus-transfection® , Illkirch, France) according to the provided manual (1 μg DNA per well in a 
6-well plate and 0.25 μg DNA per well in a 24-well plate). After 5 h, the media containing the 
transfection mix was removed and fresh media was added. After 48 h, cell viability was determined 
and cells were harvested for western blot. 
4.12. Drug Combination Analysis 
To determine whether the chemotherapeutic drug-SYK inhibitor combinations displayed a 
synergistic or additive effect, highest single agent, response additivity and Bliss independence 
calculations were performed on the cell viability data as described in [84]. Highest single agent 
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method proves the superiority of the drug combination compared to its single agents and was 
assessed with statistical testing (two-way ANOVA). Response additivity and the Bliss Independence 
model both compares the observed drug combination effect to the expected additive effect and 
thereby calculates a combination index. For Response additivity the expected additive effect is 
calculated as following: E(A) + E(B) and for the Bliss Independence: E(A) + E(B) − E(A)*E(B) where E 
is the effect produced by drug A and B. A combination index <0.9 was defined as synergistic, 0.9–1.1 
as additive and >1.1 as antagonistic. 
4.13. Statistical Analysis 
GraphPad Prism software (versions 7 and 8, GraphPad Inc., San Diego, CA, USA) was used for 
statistical analysis and graph design. Fisher’s exact test was used to test the statistical significance of 
the association between two categories. Two-way ANOVAs and Dunnett or Bonferroni post-tests 
were applied to assess two independent variables (differences between cell lines and the effect of 
treatment). Two-tailed one sample t-tests were used for the statistical analysis of the cell signaling 
studies. 
5. Conclusions 
Our findings demonstrate the presence of functional SYK in neuroblastoma tissue as well as 
certain neuroblastoma cell lines and indicate that pharmacological SYK inhibition may be a potential 
therapeutic approach that can be used to support conventional chemotherapy in SYK-expressing 
neuroblastomas. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Table S1: Clinical 
features of neuroblastoma tumors, Table S2: Cell viability of SH-SY5Y and SK-N-BE(2) after treatment with 0.8 
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